Eli Lilly (Netherlands)

Recent papers from Eli Lilly (Netherlands)

1. Dual‐Functionality, Bio‐Friendly Artificial Muscles for Actuation and Motion Sensing in Smart Wearable SystemsSmall · 2026
2. Identifying Pregnancies in Population‐Based Data Sources: Development and Application of the ConcePTION Pregnancy AlgorithmPharmacoepidemiology and Drug Safety · 2026
3. Characterising patients with Alzheimer’s disease in England: a cohort study using data from Clinical Practice Research Datalink linked to Hospital Episode StatisticsBMJ Open · 2026
4. 1L olomorasib plus pembrolizumab +/- chemotherapy in KRAS G12C-mutant NSCLC patients +/- a prior cycle of SOC: Results from LOXO-RAS 20001 and SUNRAY-01.Journal of Clinical Oncology · 2026
5. First-line (1L) olomorasib + pembrolizumab in patients with KRAS G12C–mutant advanced NSCLC, and PD-L1 expression 0-49%, from the dose optimization cohorts of LOXO-RAS-20001 and SUNRAY-01.Journal of Clinical Oncology · 2026
6. In Vivo Base Editing of PCSK9 with VERVE-102 for HypercholesterolemiaNew England Journal of Medicine · 2026
7. Outcomes of Patients with RET Fusion-Positive Non-Small Cell Lung Cancer Treated with First-Line Non-Molecularly Targeted Therapies: A Real-World Benchmark in Europe from the RECALIB-RET StudyAdvances in Therapy · 2026
8. Mutation-Specific Response to Ramucirumab in EGFR-Mutated Metastatic NSCLC: Insights From Circulating Cell-Free DNA Profiling (Liquid Biopsy Japan Addendum of RELAY Phase 3 Randomized Study)JTO Clinical and Research Reports · 2026
9. Implementation of Real-World Diagnostic Strategies in Taiwan for the Identification of Targetable Oncogenic Driver Alterations in Non–Small Cell Lung CancerJCO Global Oncology · 2025
10. RELAY: safety and efficacy of ramucirumab plus erlotinib in elderly Japanese patients with metastatic EGFR -mutated NSCLCFuture Oncology · 2025
11. RELAY+: Final Overall Survival With Ramucirumab Plus Gefitinib in Patients With Untreated EGFR-Mutated Metastatic NSCLCJTO Clinical and Research Reports · 2025
12. A Systematic Review of Algorithms for Identifying Pediatric Neurodevelopmental OutcomesPharmacoepidemiology and Drug Safety · 2025
13. Final Survival Outcomes With Ramucirumab Plus Erlotinib Versus Placebo Plus Erlotinib in Patients With Untreated EGFR-Mutated Metastatic NSCLC: RELAY Japanese SubsetJTO Clinical and Research Reports · 2025
14. RELAY: Final Overall Survival for Erlotinib Plus Ramucirumab or Placebo in Untreated, EGFR-Mutated Metastatic NSCLCJournal of Thoracic Oncology · 2024
15. Demographics, comorbidities, and comedications in newly diagnosed patients with Alzheimer's disease and related dementias: Findings from United States Medicare claims dataJournal of Alzheimer s Disease · 2024
16. SUNRAY-01, a pivotal, global study of olomorasib (LY3537982) in combination with pembrolizumab with or without chemotherapy for 1L treatment in KRAS G12C-mutant advanced NSCLC.Journal of Clinical Oncology · 2024
17. SUNRAY-01, a pivotal, global study of olomorasib (LY3537982) in combination with pembrolizumab with or without chemotherapy for 1L treatment in KRAS G12C-mutant advanced NSCLC.Journal of Clinical Oncology · 2024
18. RELAY, Erlotinib Plus Ramucirumab in Untreated, EGFR-Mutated, Metastatic NSCLC: Outcomes by EGFR Exon 19 Deletion VariantsJTO Clinical and Research Reports · 2023
19. Impact of ramucirumab plus erlotinib on circulating cell-free DNA from patients with untreated metastatic non-small cell lung cancer with EGFR-activating mutations (RELAY phase 3 randomized study)Translational Lung Cancer Research · 2023
20. RELAY, Ramucirumab Plus Erlotinib (RAM+ERL) in Untreated Metastatic EGFR-Mutant NSCLC (EGFR+ NSCLC): Association Between TP53 Status and Clinical OutcomeClinical Lung Cancer · 2023